ReviewGMS infectious diseases2018
Medical treatment for urogenital tuberculosis (UGTB).
Review in GMS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Isolated Tuberculous Testicular Abscess Without Systemic Involvement: A Rare Cause of Scrotal Swelling.Ochsner journal · 2026Article
- Isolated Prostatic Tuberculosis Coexisting with Benign Prostatic Hyperplasia: A Case Report.International medical case reports journal · 2026Article
- Renal tuberculosis with genitourinary sequelae: a case report.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Psoas muscle abscess as initial manifestation of disseminated tuberculosis in a previously healthy man: a case report.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Bilateral epididymal tuberculosis causing abscess formation and male infertility: a case report and literature review.Translational andrology and urology · 2023Article
- Article
- Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016-2018.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18-24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.